How Does Amgen’s Osteoporosis Drug EVENITY Compare to Competitors?

Following the Food and Drug Administration (FDA)’s recent approval of its osteoporosis drug romosozumab-aqqg (Evenity), Amgen has announced the medication will be available in the United States at $1,825 per monthly dose, or $21,900 for a full, one-year course of treatment. “This list price for a full course of therapy of EVENITY is 34 to … Continue reading How Does Amgen’s Osteoporosis Drug EVENITY Compare to Competitors?